A number of other brokerages have also issued reports on OHRP. Zacks Investment Research upgraded shares of Ohr Pharmaceutical from a hold rating to a strong-buy rating and set a $3.00 target price on the stock in a research note on Friday, August 26th. Roth Capital restated a buy rating and issued a $13.00 target price on shares of Ohr Pharmaceutical in a research note on Thursday, June 16th.
Shares of Ohr Pharmaceutical (NASDAQ:OHRP) traded down 0.72% during midday trading on Tuesday, reaching $2.75. 1,478 shares of the company were exchanged. The company’s 50-day moving average price is $2.73 and its 200 day moving average price is $2.93. The stock’s market capitalization is $88.28 million. Ohr Pharmaceutical has a 52-week low of $2.44 and a 52-week high of $6.56.
Ohr Pharmaceutical (NASDAQ:OHRP) last issued its quarterly earnings data on Tuesday, August 9th. The company reported ($0.24) EPS for the quarter, topping analysts’ consensus estimates of ($0.27) by $0.03. On average, equities analysts predict that Ohr Pharmaceutical will post ($0.94) earnings per share for the current year.
Several large investors have recently made changes to their positions in OHRP. GSA Capital Partners LLP acquired a new stake in shares of Ohr Pharmaceutical during the second quarter worth $144,000. Bank of New York Mellon Corp increased its stake in shares of Ohr Pharmaceutical by 1.3% in the second quarter. Bank of New York Mellon Corp now owns 60,069 shares of the company’s stock worth $164,000 after buying an additional 757 shares in the last quarter. BlackRock Fund Advisors increased its stake in shares of Ohr Pharmaceutical by 14.8% in the second quarter. BlackRock Fund Advisors now owns 75,333 shares of the company’s stock worth $206,000 after buying an additional 9,685 shares in the last quarter. Geode Capital Management LLC increased its stake in shares of Ohr Pharmaceutical by 3.9% in the first quarter. Geode Capital Management LLC now owns 152,915 shares of the company’s stock worth $490,000 after buying an additional 5,794 shares in the last quarter. Finally, Opaleye Management Inc. acquired a new stake in shares of Ohr Pharmaceutical during the first quarter worth $1,175,000. 11.32% of the stock is owned by institutional investors and hedge funds.
Receive News & Ratings for Ohr Pharmaceutical Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ohr Pharmaceutical Inc. and related companies with MarketBeat.com's FREE daily email newsletter.